Asia On The Move: As China Slows, Returnees Reconsider Options
This article was originally published in PharmAsia News
Executive Summary
The China economic slowdown appears to be starting to affect life science returnee talent, with two executives leaving their R&D and investment executive positions at top multinationals in the past few months alone. Meanwhile, the China FDA is preparing to announce a plethora of new directors and personnel changes are taking place at regional firms including ASLAN, Kyowa Hakko Kirin and Terumo.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.